Although the transfection of FLT3 expression constructs in T-ALL cell lines remains an in vitro system, the distinct sensitivity to TKIs, together with the positive experience in AML, supports the rationale for the clinical use of TKIs in ETP-ALL harboring FLT3 mutations. Here, FLT3 is linked to acute lymphoblastic leukemia.